본문 바로가기
KERD
논문KCI 등재

The Necessity of Human Papillomavirus Vaccination in Men: A Narrative Review

김수연|배상락
대한요로생식기감염학회|2024.12|Urogenital Tract Infection|제19권 제3호|pp. 51-59|DOI 10.14777/uti.2448030015

2

조회

0

다운로드

1

인용

0

참고문헌

키워드

VaccinationHuman papillomavirusUterine cervical neoplasmsOropharyngeal neoplasmsCondyloma acuminata
주제분류비뇨기과학

초록

Anogenital wart caused by human papillomavirus (HPV) is the most common sexually transmitted infection. High-risk strains, such as types 16 and 18, cause penile cancer in men, cervical and vulvar cancers in women, and head and neck cancers and anal cancer in both sexes. Since these malignant tumors can be prevented through vaccination, the importance of vaccination is emphasized. However, because HPV is known to cause cervical cancer, vaccination is only being administered to women. Some countries vaccinate men as well, but in South Korea, only girls are included in the National Immunization Program. However, screening for HPV in men is not possible, and the virus causes various malignant tumors, with a sharp increase in head and neck cancers, as well as a surge in genital warts in the country. In addition, HPV worsens sperm quality. Moreover, the need for vaccines is increasing as the known methods for preventing HPV-related diseases in men are decreasing and the disease burden is increasing. As cost-effectiveness studies have shown that the cost-effectiveness of vaccination is lower for men than for women, it is unlikely that male vaccination will be included in national immunization programs. Many countries overseas, especially a very small number of OECD (Organization for Economic Cooperation and Development) countries including South Korea, are implementing mandatory vaccination for women. Vaccinating men and women, would be cost-effective and efficient in achieving herd immunity. In addition to herd immunity, the inclusion of male vaccination in the National Immunization Program is imperative given the rapidly increasing incidence of diseases in men.

Abstract

Anogenital wart caused by human papillomavirus (HPV) is the most common sexually transmitted infection. High-risk strains, such as types 16 and 18, cause penile cancer in men, cervical and vulvar cancers in women, and head and neck cancers and anal cancer in both sexes. Since these malignant tumors can be prevented through vaccination, the importance of vaccination is emphasized. However, because HPV is known to cause cervical cancer, vaccination is only being administered to women. Some countries vaccinate men as well, but in South Korea, only girls are included in the National Immunization Program. However, screening for HPV in men is not possible, and the virus causes various malignant tumors, with a sharp increase in head and neck cancers, as well as a surge in genital warts in the country. In addition, HPV worsens sperm quality. Moreover, the need for vaccines is increasing as the known methods for preventing HPV-related diseases in men are decreasing and the disease burden is increasing. As cost-effectiveness studies have shown that the cost-effectiveness of vaccination is lower for men than for women, it is unlikely that male vaccination will be included in national immunization programs. Many countries overseas, especially a very small number of OECD (Organization for Economic Cooperation and Development) countries including South Korea, are implementing mandatory vaccination for women. Vaccinating men and women, would be cost-effective and efficient in achieving herd immunity. In addition to herd immunity, the inclusion of male vaccination in the National Immunization Program is imperative given the rapidly increasing incidence of diseases in men.

참고문헌 (51)

  1. Oyouni AAA, "Human papillomavirus in cancer : Infection, disease transmission, and progress in vaccines", J Infect Public Health, 16, pp.626~631 (2023)
  2. Schiffman M, "Carcinogenic human papillomavirus infection", Nat Rev Dis Primers, 2, pp.16086~ (2016)
  3. Williamson AL, "Recent developments in human papillomavirus(HPV)vaccinology", Viruses, 15, pp.1440~ (2023)
  4. Malagón T, "Human papillomavirus vaccination and the role of herd effects in future cancer control planning : a review", Expert Rev Vaccines, 17, pp.395~409 (2018)
  5. Simons JJM, "Cost-effectiveness analysis of a gender-neutral human papillomavirus vaccination program in the Netherlands", Vaccine, 38, pp.4687~4694 (2020)
  6. Gray P, "Human papillomavirus seroprevalence in pregnant women following gender-neutral and girls-only vaccination programs in Finland : A cross-sectional cohort analysis following a cluster randomized trial", PLoS Med, 18, pp.e1003588~ (2021)
  7. Wolff E, "Cost-effectiveness of sex-neutral HPV-vaccination in Sweden, accounting for herd-immunity and sexual behaviour", Vaccine, 36, pp.5160~5165 (2018)
  8. Verheijen RHM, "EBCOG position statement : Gender neutral HPV vaccination for young adults", Eur J Obstet Gynecol Reprod Biol, 246, pp.187~189 (2020)
  9. Durham DP, "National-and state-level impact and cost-effectiveness of nonavalent HPV vaccination in the United States", Proc Natl Acad Sci U S A, 113, pp.5107~5112 (2016)
  10. Solomon IH, "Diagnostic pathology: infectious diseases-E-BOOK" (2024), Elsevier Health Sciences
  11. Brianti P, "Review of HPV-related diseases and cancers", New Microbiol, 40, pp.80~85 (2017)
  12. Giuliano AR, "Age-specific prevalence, incidence, and duration of human papillomavirus infections in a cohort of 290 US men", J Infect Dis, 198, pp.827~835 (2008)
  13. Tommasino M, "HPV and skin carcinogenesis", Papillomavirus Res, 7, pp.129~131 (2019)
  14. Weiss RA, "On viruses, discovery, and recognition", Cell, 135, pp.983~986 (2008)
  15. de Martel C, "Worldwide burden of cancer attributable to HPV by site, country and HPV type", Int J Cancer, 141, pp.664~670 (2017)
  16. Ogbuji V, "Global burden of penile cancer : a review of health disparities for a rare disease", Urology, 194, pp.280~288 (2024)
  17. Serrano B, "Epidemiology and burden of HPV-related disease", Best Pract Res Clin Obstet Gynaecol, 47, pp.14~26 (2018)
  18. Roman BR, "Epidemiology and incidence of HPV-related cancers of the head and neck", J Surg Oncol, 124, pp.920~922 (2021)
  19. Arbyn M, "Estimates of incidence and mortality of cervical cancer in 2018 : a worldwide analysis", Lancet Glob Health, 8, pp.e191~e203 (2020)
  20. Malagón T, "Sex-and type-specific genital human papillomavirus transmission rates between heterosexual partners : a Bayesian Reanalysis of the HITCH Cohort", Epidemiology, 32, pp.368~377 (2021)
  21. de Sanjosé S, "Burden of human papillomavirus(HPV)-related cancers attributable to HPVs 6", 11, 18, pp.31, 33[DOI]
  22. de Martel C, "Global burden of cancer attributable to infections in 2018 : a worldwide incidence analysis", Lancet Glob Health, 8, pp.e180~e190 (2020)
  23. Park YJ, "Annual prevalence and economic burden of genital warts in Korea : Health Insurance Review and Assessment(HIRA)service data from 2007to 2015", Epidemiol Infect, 146, pp.177~186 (2018)
  24. Chung H, "Prevalence and economic burden of male anogenital wart in Korea : A population-based big data analysis from 2007 to 2018", Investig Clin Urol, 65, pp.579~586 (2024)
  25. Kim EJ, "Trends of genital wart in Korea according to treatment method classification : Big data analysis of health care in 2010-2019", Investig Clin Urol, 64, pp.56~65 (2023)
  26. Van Dyne EA, "Trends in human papillomavirus-associated cancers-United States, 1999-2015", MMWR Morb Mortal Wkly Rep, 67, pp.918~924 (2018)
  27. Brenner DR, "Projected estimates of cancer in Canada in 2024", CMAJ, 196, pp.E615~E623 (2024)
  28. Park JO, "Sex differences in the prevalence of head and neck cancers : a 10-year follow-up study of 10 million healthy people", Cancers(Basel), 14, pp.2521~ (2022)
  29. Iorga L, "Penile carcinoma and HPV infection(Review)", Exp Ther Med, 20, pp.91~96 (2020)
  30. Mannam G, "HPV and penile cancer : epidemiology, risk factors, and clinical insights", Pathogens, 13, pp.809~ (2024)
  31. Cho S, "Twenty-two-year incidence trend of urological cancers in the Republic of Korea : 1999-2020", Investig Clin Urol, 65, pp.23~31 (2024)
  32. Fife KH, "Poor sensitivity of polymerase chain reaction assays of genital skin swabs and urine to detect HPV 6 and 11 DNA in men", Sex Transm Dis, 30, pp.246~248 (2003)
  33. Dunne EF, "Prevalence of HPV infection among men : a systematic review of the literature", J Infect Dis, 194, pp.1044~1057 (2006)
  34. D'Hauwers KW, "Screening for human papillomavirus : is urine useful?", Indian J Cancer, 46, pp.190~193 (2009)
  35. D'Souza G, "Evaluating the utility and prevalence of HPV biomarkers in oral rinses and serology for HPV-related oropharyngeal cancer", Cancer Prev Res(Phila), 12, pp.689~700 (2019)
  36. Poljak M, "Testing for human papillomaviruses in urine, blood, and oral specimens : an update for the laboratory", J Clin Microbiol, 61, pp.e0140322~ (2023)
  37. Ahn S, "(370)The Prevalence and Genotype Distribution of Human Papillomaviruses among Men in Korea", J Sex Med, 20(Supplement 1), pp.qdad060.344~ (2023)[DOI]
  38. Elfström KM, "Human papillomavirus vaccination of boys and extended catch-up vaccination : effects on the resilience of programs", J Infect Dis, 213, pp.199~205 (2016)
  39. Lehtinen M, "Gender-neutrality, herd effect and resilient immune response for sustainable impact of HPV vaccination", Curr Opin Obstet Gynecol, 27, pp.326~332 (2015)
  40. Bruni L, "HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010-2019", Prev Med, 144, pp.106399~ (2021)
  41. Shim HW, "Economic evaluation of human papillomavirus vaccination", pp.2021
  42. Linertová R, "Cost-effectiveness of extending the HPV vaccination to boys : a systematic review", J Epidemiol Community Health, 75, pp.910~916 (2021)
  43. Friedman B, "Pros and cons of circumcision : an evidence-based overview", Clin Microbiol Infect, 22, pp.768~774 (2016)
  44. Mehta KS, "Male circumcision and sexually transmitted infections-an update", Indian J Sex Transm Dis AIDS, 42, pp.1~6 (2021)
  45. Smith JS, "Male circumcision reduces penile HPV incidence and persistence : a randomized controlled trial in Kenya", Cancer Epidemiol Biomarkers Prev, 30, pp.1139~1148 (2021)
  46. Shapiro SB, "Association between male circumcision and human papillomavirus infection in males and females : a systematic review, meta-analysis, and meta-regression", Clin Microbiol Infect, 29, pp.968~978 (2023)
  47. Cao X, "Impact of human papillomavirus infection in semen on sperm progressive motility in infertile men : a systematic review and meta-analysis", Reprod Biol Endocrinol, 18, pp.38~ (2020)
  48. Boeri L, "High-risk human papillomavirus in semen is associated with poor sperm progressive motility and a high sperm DNA fragmentation index in infertile men", Hum Reprod, 34, pp.209~217 (2019)
  49. Foresta C, "Human papillomavirus found in sperm head of young adult males affects the progressive motility", Fertil Steril, 93, pp.802~806 (2010)
  50. Garolla A, "Human papillomavirus prophylactic vaccination improves reproductive outcome in infertile patients with HPV semen infection : a retrospective study", Sci Rep, 8, pp.912~ (2018)
  51. Lyu Z, "Human papillomavirus in semen and the risk for male infertility : a systematic review and meta-analysis", BMC Infect Dis, 17, pp.714~ (2017)

이 간행물의 다른 논문 (8건)

Urogenital Tract Infection Reaches a Global Audience유구한pp. 49-50Mechanistic Insights Into Persistent Bacterial Cystitis as a Basis for Vaccine Development: A Narrative ReviewKaren Serrano-Arevalo, 최해웅, Manisha Naskarpp. 60-72Postoperative Microscopic Pyuria and Role of Damage-Associated Molecular Pattern: A Literature Review김민규, 김기홍pp. 73-79Artificial Intelligence for Autonomous Robotic Surgery in Urology: A Narrative Review양희조, 이대영pp. 80-88Impact of the Timing of Percutaneous Nephrostomy on the Prognosis of Obstructive Urolithiasis With Sepsis: A Retrospective Cohort Study장영섭, 김진범, 김홍욱, 유지은, 고동훈, 김형준pp. 89-96
원문 보기